APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies the side effects of CD40 agonistic monoclonal antibody
APX005M (APX005M), chemotherapy, and radiation therapy, and to see how well they work when
given before surgery in treating patients with esophageal cancer or gastroesophageal cancer
that can be removed by surgery. APX005M is intended to stimulate the body's own immune system
so that the immune cells can more effectively invade and destroy the tumor, adding to the
benefits of the chemotherapy and radiation therapy. Drugs used in chemotherapy, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving
APX005M, chemotherapy, and radiation therapy before surgery may make the tumor smaller and
reduce the amount of normal tissue that needs to be removed.
Phase:
Phase 2
Details
Lead Sponsor:
Apexigen, Inc. University of California, San Francisco